Partikula is a biotechnology and healthcare startup founded in 2013 and headquartered in the United States. The company leverages its exclusive chemical engineering technologies to create compounds that specifically target mitochondria, ranging from the outer mitochondrial membrane to the mitochondrial matrix and areas in between. This approach allows them to address a wide range of challenging targets that have been difficult to reach with traditional therapies. Partikula's initial clinical focus is in oncology, with ongoing development programs in early stages for neurodegenerative, cardiovascular, and orphan mitochondrial diseases. The company received a $550.00K Venture Round investment on 13 February 2015.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Venture Round | $550.00K | - | 13 Feb 2015 |
No recent news or press coverage available for Partikula LLC.
We care about your data, and we'd love to use cookies make your experience better.